Korea South
Galux, founded in 2020, is at the forefront of biotechnology, leveraging the synergy of AI, physics, and chemistry. Based in South Korea, their mission is encapsulated in their slogan: "Biotech leveraging AI, physics, and chemistry to design novel drugs against attractive targets."
The company has a strong technological foundation rooted in 15 years of molecular design research from Seoul National University. Galux is developing a cutting-edge drug design platform focused on protein structure prediction, protein-protein interaction prediction, and protein-ligand interaction prediction. Their platform is particularly aimed at uncovering novel therapeutics for incurable and rare diseases, setting them apart in the AI and Biotechnology industries.
Although they have not yet announced a last investment round or investors, Galux's robust research capabilities and innovative approach present a compelling case for potential investment.
